BioCurex, Inc.(fka BOCX)

[HALF FULL GLASS]

One would believe that a pharma would be interested in a biomarker that can provide real time information showing if a cancer is decreasing during treatment...

The study also showed a significant drop in circulating RECAF for patients after surgery.  The drop was most pronounced in those patients with the highest RECAF values before surgery.  Samples taken after longer intervals following surgery exhibited the highest drops.

Dr. Ricardo Moro, BioCurex CEO stated, "These results clearly indicate that RECAF is increased in patients with early stages of breast cancer, and that RECAF decreases in those same patients after surgery.  If the original cancer produced an excess of RECAF, its recurrence would also produce excessive RECAF and therefore be detectable with our RECAF test. Also, if 90% of early stage cancers are detectable, recurrence in those cases should also be detected early with the resulting benefit for the patient.  These results are the first step in demonstrating that our blood test for cancer can be used to monitor therapy and follow-up treated patients for early detection of recurrence."